Update of the prostate, lung, colorectal, and ovarian cancer screening trial

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

11 Scopus citations

Abstract

The prostate portion of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial began in the early 1990s to assess the ability of annual PSA and DRE to reduce prostate cancer specific mortality in men aged 55-74. Approximately 80,000 men have been randomized and followed for a minimum of 13 years. Thus far, annual screening in this study has not been associated with a reduction of prostate cancer specific mortality. The potential explanations for this finding are reviewed.

Original languageEnglish
Title of host publicationProstate Cancer Prevention
PublisherSpringer New York LLC
Pages53-57
Number of pages5
ISBN (Print)9783642451942
DOIs
StatePublished - 2014

Publication series

NameRecent Results in Cancer Research
Volume202
ISSN (Print)0080-0015

Fingerprint Dive into the research topics of 'Update of the prostate, lung, colorectal, and ovarian cancer screening trial'. Together they form a unique fingerprint.

Cite this